PT  - JOURNAL ARTICLE
AU  - WALTER RHOMBERG
AU  - HELMUT EITER
AU  - FRANZ SCHMID
AU  - CHRISTOPH SAELY
TI  - Razoxane and Vindesine in Advanced Soft Tissue Sarcomas: Impact on Metastasis, Survival and Radiation Response
DP  - 2007 Sep 01
TA  - Anticancer Research
PG  - 3609--3614
VI  - 27
IP  - 5B
4099  - http://ar.iiarjournals.org/content/27/5B/3609.short
4100  - http://ar.iiarjournals.org/content/27/5B/3609.full
SO  - Anticancer Res2007 Sep 01; 27
AB  - Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti-metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0-70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p<0.001). The progression-free survival at 6 months was 71% in the study group and 23% in the controls, and the median survival time from the occurrence of the first metastasis was 16 months versus 9 months. The rate of major responses under radiotherapy combined with razoxane and vindesine was 88%, and in the control group 62% (p=0.007). The combined treatment was associated with a low to moderate toxicity. Conclusion: The treatment combination inhibited the development of remote metastases in the majority of patients with STS and prolonged survival to some extent. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved